MoonLake Immunotherapeutics (NASDAQ:MLTX) is one of the 10 Stocks with Huge Catalysts on the Horizon. The company speeds up the clinical momentum with phase 3 trials, expanded indications, and ...

CT-155, an investigational prescription digital therapeutic, is safe and effective in reducing negative schizophrenia symptoms, early phase 3 trial results suggest.

Topline results were announced from a second phase 3 trial evaluating AD109 (aroxybutynin 2.5mg/atomoxetine 75mg) in patients with obstructive sleep apnea (OSA).

Click and Boehringer Ingelheim make progress in software-enhanced drug treatment for schizophrenia with a positive phase 3 trial of their CT-155 app ...

GUNTUR: In a major push to Guntur’s long-stalled infrastructure development, the phase-3 of the city’s Inner Ring Road (IRR) project is finally moving forward.

BriaCell’s pivotal Phase 3 clinical study is evaluating BriaCell’s lead clinical candidate, Bria-IMT™, plus immune check point inhibitor (CPI) versus physician’s choice in advanced metastatic breast ...

Hengrui has tied its GLP-1/GIP agonist to weight loss of almost 18% at 48 weeks, leading the biotech to push for China approval “as soon as possible.” ...

Bristol Myers braves failed Reblozyl phase 3, plans FDA talks for potential anemia expansion By Angus Liu Jul 18, 2025 11:28am Bristol Myers Squibb Reblozyl myelofibrosis Anemia drugs ...

After its lead wet AMD drug failed a phase 3 trial, Opthea may have to make massive repayments to investors that would threaten its viability.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is leading innovation in treating metabolic dysfunction-associated steatohepatitis (MASH), previously known as NASH.